Imeglimin Monohydrochloride is a first-in-class oral antidiabetic agent belonging to the glimin class, a family of tetrahydrotriazine-containing compounds. Designed to treat type 2 diabetes mellitus, it… Read more
Imeglimin Monohydrochloride is a first-in-class oral antidiabetic agent belonging to the glimin class, a family of tetrahydrotriazine-containing compounds. Designed to treat type 2 diabetes mellitus, it functions through a unique mechanism that modulates mitochondrial bioenergetics to improve insulin sensitivity and enhance glucose-stimulated insulin secretion. This category provides essential materials for pharmaceutical research and development, including high-quality reference standards of the active pharmaceutical ingredient. Laboratories utilize these compounds to conduct rigorous impurity profiling and metabolite identification, ensuring the accuracy of analytical testing and quality control protocols. Furthermore, the availability of stable isotope labelled versions of these molecules supports precise quantification and pharmacokinetic studies, facilitating the validation of testing methods required to meet regulatory and quality standards throughout the drug development lifecycle.